test3

Attention Virginia Cancer Specialists Patients: There is a system outage and certain functions, such as scheduling, may not be available today. We will call patients to schedule any upcoming appointments when the system is back online. Our clinics remain open and previously scheduled appointments will continue as planned. We apologize for any inconvenience.

 

Alexander I Spira, MD, PhD, FACP - presents key study at ASCO 2022 - Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

Virginia Cancer Specialists Practice Blog

June 03, 2022
Virginia Cancer Specialists » VCS Practice News » Blog Post » Alexander I Spira, MD, PhD, FACP – presents key study at ASCO 2022 – Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

https://www.onclive.com/view/adagrasib-elicits-deep-and-durable-responses-in-pretreated-kras-g12c-mutant-nsclc

At the meeting, Alexander I. Spira, MD, PhD, FACP, co-director of Virginia Cancer Specialists Research Institute, director of the Thoracic and Phase I Program, and clinical assistant professor at Johns Hopkins School of Medicine, presented data as of October 15, 2021, from the registrational phase 2 cohort A study, which was simultaneously published in the New England Journal of Medicine.